The problem is that if the in-vitro studies are correct on their dose curves, then the majority of the human trials are at ineffective doses. This doesn't mean

The problem is that if the in-vitro studies are correct on their dose curves, then the majority of the human trials are at ineffective doses. This doesn't mean they must be wrong, but it's not a good look. If the studies were showing unequivocal benefit, we could overlook the dose curves. But the studies are still quite equivocal. On the other hand, molnupirivir is a nucleoside polymerase inhibitor, with a slam-dunk mechanism of action, evidence of efficacy against a broad range of viruses, and increasingly compelling human safety profile. I don't know if Merck is stalling but the ivermectin case is certainly less compelling. https://www.science.org/content/blog-post/ivermectin-covid-19-therapy https://www.science.org/content/blog-post/ivermectin-covid-1...